image: Shown is the protein structure of the tumor-targeting 4-1BBL molecule. This material relates to a paper that appeared in the Jun. 19, 2019, issue of Science Translational Medicine, published by AAAS. The paper, by C. Claus at Roche Innovation Center Zurich in Schlieren, Switzerland; and colleagues was titled, "Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy." view more
Credit: [Credit: Dr. Alexander Bujotzek and Dr. Guy Georges at Roche Innovation Center Munich; Dr. Jörg Benz at Roche Innovation Center Basel]